National Jewish Health: Research Shows Medication Effective in Treatment of Children With Atopic Dermatitis
December 05, 2024
December 05, 2024
DENVER, Colorado, Dec. 5 (TNSres) -- National Jewish Health, a respiratory hospital, issued the following news release:
Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms of moderate-to-severe atopic dermatitis (eczema) in young children whether or not they have another inflammatory condition, such as asthma, allergic rhinitis or food allergies. Dupilumab had previously been shown to be effective in the treatme . . .
Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms of moderate-to-severe atopic dermatitis (eczema) in young children whether or not they have another inflammatory condition, such as asthma, allergic rhinitis or food allergies. Dupilumab had previously been shown to be effective in the treatme . . .